Angiopoietins in angiogenesis and beyond

Expert Opinion on Investigational Drugs

Volumn 12, Issue 6, 2003, Pages 933-941

  Tsigkos, Stelios ^a   Koutsilieris, Micheal ^b   Papapetropoulos, Andreas ^a,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Angiogenesis; Angiopoietins; Cancer; Endothelium; Tie2

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 3; ANGIOPOIETIN 4; ANGIOPOIETIN RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CANCER; CARDIOVASCULAR SYSTEM; CELL SURVIVAL; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; GENETIC MODEL; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SPROUTING; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANGIOPOIETINS; ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2;

EID: 0038685933     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.6.933     Document Type: Review

References (93)

1. RISAU W: Mechanisms of angiogenesis. Nature (1997) 386:671-674.
2. CARMELIET P: Mechanisms of angiogenesis and arteriogenesis. Nat. Med. (2000) 6:389-395.
3. GALE NW, YANCOPOULOS GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. (1999) 13:1055-1066.
4. DUMONT DJ, YAMAGUCHI TP, CONLON RA et al.: Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene (1992) 7:1471-1480.
5. MAISONPIERRE PC, GOLDFARB M, YANCOPOULOS GD et al.: Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene (1993) 8:1631-1637.
6. PARTANEN J, ARMSTRONG E, MAKELA TP et al.: A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol. (1992) 12:1698-1707.
7. SATO TN, QIN Y, KOZAK CA et al.: Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc. Natl. Acad. Sci. USA (1993) 90:9355-9358.
8. XU Y, YU Q: Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J. Biol. Chem. (2001) 276:34990-34998.
9. MARRON MB, HUGHES DP, EDGE MD et al.: Evidence for heterotypic interaction between the receptor tyrosine kinases TIE- 1 and TIE-2. J. Biol. Chem. (2000) 275:39741-39746.
10. TSIAMIS AC, MORRIS PN, MARRON MB et al.: Vascular endothelial growth factor modulates the Tie-2: Tie-1 receptor complex. Microvasc. Res. (2002) 63:149-158.
11. YABKOWITZ R, MEYER S, BLACK T et al.: Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood (1999) 93:1969-1979.
12. KONTOS CD, CHA EH, YORK JD et al.: The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol. Cell. Biol. (2002) 22:1704-1713.
13. WONG AL, HAROON ZA, WERNER S et al.: Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ. Res. (1997) 81:567-574.
14. MULLER A, LANGE K, GAISER T et al.: Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk. Res. (2002) 26:163-168.
15. WILLAM C, KOEHNE P, JURGENSEN JS et al.: Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ. Res. (2000) 87:370-377.
16. DAVIS S, ALDRICH TH, JONES PF et al.: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 87:1161-1169.
17. MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277:55-60.
18. VALENZUELA DM, GRIFFITHS JA, ROJAS J et al.: Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. USA (1999) 96:1904-1909.
19. KIM I, KIM JH, MOON SO et al.: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene (2000) 19:4549-4552.
20. TEICHERT-KULISZEWSKA K, MAISONPIERRE PC, JONES N et al.: Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc. Res. (2001) 49:659-670.
21. ASAHARA T, CHEN D, TAKAHASHI T et al.: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. (1998) 83:233-240.
22. GALE N, THURSTON G, HACKETT S et al.: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell (2002) 3:411.
23. LOBOV IB, BROOKS PC, LANG RA: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc. Natl. Acad. Sci. USA (2002) 99:11205-11210.
24. VISCONTI RP, RICHARDSON CD, SATO TN: Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc. Natl. Acad. Sci. USA (2002) 99:8219-8224.
25. PROCOPIO WN, PELAVIN PI, LEE WM et al.: Angiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J. Biol. Chem. (1999) 274:30196-30201.
26. MANDRIOTA SJ, PEPPER MS: Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res. (1998) 83:852-859.
27. WITZENBICHLER B, MAISONPIERRE PC, JONES P et al.: Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J. Biol. Chem. (1998) 273:18514-18521.
28. HUANG YQ, LI JJ, HU L et al.: Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood (2002) 99:1646-1650.
29. KRIKUN G, SCHATZ F, FINLAY T et al.: Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem. Biophsy. Res. Commun. (2000) 275:159-163.
30. OH H, TAKAGI H, SUZUMA K et al.: Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. (1999) 274:15732-15739.
31. COHEN B, BARKAN D, LEVY Y et al.: Leptin induces angiopoietin-2 expression in adipose tissues. J. Biol. Chem. (2001) 276:7697-7700.
32. ENHOLM B, PAAVONEN K, RISTIMAKI A et al.: Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 14:2475-2483.
33. KRIKUN G, CRITCHLEY H, SCHATZ F et al.: Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression. Am. J. Pathol. (2002) 161:979-986.
34. YE F, FLORIAN M, MAGDER SA et al.: Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen. Steroids (2002) 67:305-310.
35. SATO TN, TOZAWA Y, DEUTSCH U et al.: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 376:70-74.
36. SURI C, JONES PF, PATAN S et al.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 87:1171-1180.
37. SURI C, MCCLAIN J, THURSTON G et al.: Increased vascularization in mice overexpressing angiopoietin-1. Science (1998) 282:468-471.
38. THURSTON G, SURI C, SMITH K et al.: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 286:2511-2514.
39. THURSTON G, RUDGE J, IOFFE E et al.: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med (2000) 6:460-463.
40. VIKKULA M, BOON LM, CARRAWAY KL 3rd et al.: Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell (1996) 87:1181-1190.
41. KOBLIZEK TI, WEISS C, YANCOPOULOS GD et al.: Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. (1998) 8:529-532.
42. KWAK HJ, SO JN, LEE SJ et al.: Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett. (1999) 448:249-253.
43. PAPAPETROPOULOS A, GARCIA-CARDENA G, DENGLER TJ et al.: Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest. (1999) 79:213-223.
44. HARFOUCHE R, HASSESSIAN HM, GUO Y et al.: Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc. Res. (2002) 64:135-147.
45. PAPAPETROPOULOS A, FULTON D, MAHBOUBI K et al.: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. (2000) 275:9102-9105.
46. HAYES AJ, HUANG WQ, MALLAH J et al.: Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc. Res. (1999) 58:224-237.
47. MOCHIZUKI Y, NAKAMURA T, KANETAKE H et al.: Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J. Cell Sci. (2002) 115:175-183.
48. GAMBLE JR, DREW J, TREZISE L et al.: Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. (2000) 87:603-607.
49. KIM I, MOON SO, PARK SK et al.: Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ. Res. (2001) 89:477-479.
50. KIM I, OH JL, RYU YS et al.: Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J. (2002) 16:12-128.
51. KIM I, KIM HG, MOON SO et al.: Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ. Res. (2000) 86:952-959.
52. JONES N, MASTER Z, JONES J et al.: Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J. Biol. Chem. (1999) 274:30896-30905.
53. KONTOS CD, STAUFFER TP, YANG WP et al.: Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol. Cell. Biol. (1998) 18:4131-4140.
54. FUJIKAWA K, DE AOS SCHERPENSEEL I, JAIN SK et al.: Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp. Cell. Res. (1999) 253:663-672.
55. HUANG L, TURCK CW, RAO P et al.: GRB2 and SH-PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Oncogene (1995) 11:2097-2103.
56. JONES N, DUMONT DJ: The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene (1998) 17:1097-1108.
57. JONES N, ILJIN K, DUMONT DJ et al.: Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat. Rev. Mol. Cell. Biol. (2001) 2:257-267.
58. FACHINGER G, DEUTSCH U, RISAU W: Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene (1999) 18:5948-5953.
59. RAJANTIE I, EKMAN N, ILJIN K et al.: Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol. Cell. Biol. (2001) 21:4647-4655.
60. KORPELAINEN EI, KARKKAINEN M, GUNJI Y et al.: Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene (1999) 18:1-8.
61. FOLKMAN J: What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. (1990) 82:4-6.
62. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353-364.
63. HOLASH J, WIEGAND SJ, YANCOPOULOS GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 18:5356-5362.
64. HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284:1994-1998.
65. STRATMANN A, RISAU W. PLATE KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. (1998) 153:1459-1466.
66. EGGERT A, IKEGAKI N, KWIATKOWSKI J et al.: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. (2000) 6:1900-1908.
67. HAYES AJ, HUANG WQ, YU J et al.: Expression and function of angiopoietin-1 in breast cancer. Br. J. Cancer (2000) 83:1154-1160.
68. CURRIE MJ, GUNNINGHAM SP, HAN C et al.: Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin. Cancer Res. (2001) 7:918-927.
69. HATANAKA H, ABE Y, NARUKE M et al.: Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin. Cancer Res. (2001) 7:1287-1292.
70. TANAKA S, MORI M, SAKAMOTO Y et al.: Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J. Clin. Invest. (1999) 103:341-345.
71. KURODA H, OHTSURU A, FUTAKUCHI M et al.: Distinctive gene expression of receptor-type tyrosine kinase families during rat hepatocarcinogenesis. Int. J. Mol. Med. (2002) 9:473-480.
72. ETOH T, INOUE H, TANAKA S et al.: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. (2001) 61:2145-2153.
73. AHMAD SA, LIU W, JUNG YD et al.: The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. (2001) 61:1255-1259.
74. BROWN LF, DEZUBE BJ, TOGNAZZI K et al.: Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am. J. Pathol. (2000) 156:2179-2183.
75. YU Y, VARUGHESE J, BROWN LF et al.: Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am. J. Pathol. (2001) 159:2271-2280.
76. POMYJE J, ZIVNY JH, STOPKA T et al.: Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma. Melanoma Res. (2001) 11:639-643.
77. HAWIGHORST T, SKOBE M, STREIT M et al.: Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am. J. Pathol. (2002) 160:1381-1392.
78. BUNONE G, VIGNERI P, MARIANI L et al.: Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. (1999) 155:1967-1976.
79. AGUAYO A, KANTARJIAN H, MANSHOURI T et al.: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 96:2240-2245.
80. ALBITAR M: Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. (2001) 106:170-176.
81. LIN P, POLVERINI P, DEWHIRST M et al.: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. (1997) 100:2072-2078.
82. LIN P, BUXTON JA, ACHESON A et al.: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA (1998) 95:8829-8834.
83. CARTER WB, WARD MD: HER2 regulatory control of angiopoietin-2 in breast cancer. Surgery (2000) 128:153-158.
84. MARTOGLIO AM, TOM BD, STARKEY M et al.: Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol. Med. (2000) 6:750-765.
85. ZAGZAG D, HOOPER A, FRIEDLANDER DR et al.: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early market of tumor angiogenesis. Exp. Neurol. (1999) 159:391-400.
86. JONES MK, KAWANAKA H, BAATAR D et al.: Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology (2001) 121:1040-1047.
87. KARMPALIOTIS D, KOSMIDOU I, INGENITO EP et al.: Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J. Physiol. Lung Cell. Mol. Physiol. (2002) 283:L585-L595.
88. JOUSSEN AM, POULAKI V, TSUJIKAWA A et al.: Suppression of diabetic retinopathy with angiopoietin-1. Am. J. Pathol. (2002) 160:1683-1693.
89. HUGHES DP, MARRON MB, BRINDLE NP: The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ. Res. (2003) 92:630-636.
90. NYKANEN AI, KREBS R, SAARISTO A et al.: Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation (2003) 107:1308-1314.
91. DU L, SULLIVAN CC, CHU D et al.: Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. (2003) 348:500-509.
92. ZHAO YD, CAMPBELL AI, ROBB M et al.: Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ. Res. (2003) 92(9):994-991.
93. SHUY K-G, MANOR O, MAGNER BS et al.: Direct intramuscular injection of plasmid DNA endoding angiopoietin-1, but not angiopoietin-2, augments revascularization in the rabbit ischemic limb. Circulation (1998) 98:2081-2087.